Category: 34595-33-0

A catalyst don’t appear in the overall stoichiometry of the reaction it catalyzes, Application In Synthesis of 5-Amino-2-(piperidin-1-yl)benzonitrile, but it must appear in at least one of the elementary reactions in the mechanism for the catalyzed reaction. 34595-33-0, Name is 5-Amino-2-(piperidin-1-yl)benzonitrile, molecular formula is C12H15N3. In a Article, authors is Grell, Wolfgang，once mentioned of 34595-33-0

The structure-activity relationships in two series of hypoglycemic benzoic acid derivatives (5, 6) were investigated. Series 5 resulted from meglitinide (3) when the 2-methoxy was replaced by an alkyleneimino residue. Maximum activity was observed with the cis-3,5-dimethylpiperidino (5h) and the octamethyleneimino (5l) residues. Series 6 resulted from the meglitinide analogon 4 bearing an inversed amido function when the 2-methoxy, the 5- fluoro, and the alpha-methyl residue were replaced by a 2-piperidino, a 5- hydrogen, and a larger alpha-alkyl residue, respectively. An alkoxy residue ortho to the carboxy group further increased activity and duration of action in the rat. The most active racemic compound, 6al (R4 = isobutyl; R = ethoxy), turned out to be 12 times more active than the sulfonylurea (SU) glibenclamide (1). Activity was found to reside predominantly in the (S)- enantiomers. Compared with the SUs 1 and 2 (glimepiride), the most active enantiomer, (S)-6al (AG-EE 623 ZW; repaglinide; ED50 = 10 mug/kg po), is 25 and 18 times more active. Repaglinide turned out to be a useful therapeutic for type 2 diabetic patients; approval was granted recently by the FDA and the EMEA. From investigations on the pharmacophoric groups in compounds of type 5 and 6, it was concluded that in addition to the two already known – the acidic group (COOH; S02NH) and the amidic spacer (CONH; NHCO) – the ortho residue R1 (alkyleneimino; alkoxy; oxo) must be regarded as a third one. A general pharmacophore model suitable for hypoglycemic benzoic acid derivatives, SUs, and sulfonamides is proposed (Figure 6). Furthermore, from superpositions of low-energy conformations (LECs) of 1, 2, and (S)-6al, it was concluded that a common binding conformation (LEC II; Figure 10B) may exist and that differences in binding to the SU receptor and in the mechanism of insulin release between repaglinide and the two SUs may be due to specific hydrophobic differences.

I hope this article can help some friends in scientific research. I am very proud of our efforts over the past few months and hope to 34595-33-0, help many people in the next few years.Application In Synthesis of 5-Amino-2-(piperidin-1-yl)benzonitrile

Reference：
Piperidine – Wikipedia,
Piperidine | C5H14704N – PubChem

Electric Literature of 34595-33-0, A catalyst don’t appear in the overall stoichiometry of the reaction it catalyzes, but it must appear in at least one of the elementary reactions in the mechanism for the catalyzed reaction. 34595-33-0, Name is 5-Amino-2-(piperidin-1-yl)benzonitrile, molecular formula is C12H15N3. In a Patent，once mentioned of 34595-33-0

The present invention provides a compound represented by the formula (I) 1wherein ring A is benzene, cyclohexane, pyridine, piperidine or a derivative thereof, imidazole or a derivative thereof and the like, ring B is benzene, cyclohexane, pyrrole or a derivative thereof, furan, thiophene and the like, R1, R2 and R3 are each hydrogen, alkyl, halogen, hydroxyl group, alkoxy and the like, W is hydrogen, alkyl or hydroxycarbonylalkyl, X is halogen, cyano, nitro and the like, X? is hydrogen, halogen and the like, and Y is alkyl, hydroxyalkyl, hydroxycarbonylalkyl, aminoalkyl and the like, a salt thereof, and a pharmaceutical agent containing the compound. The compound of the present invention shows a superior inhibitory effect on the proliferation of activated lymphocyte and is useful as an agent for the prophylaxis or treatment of various autoimmune diseases.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.Electric Literature of 34595-33-0, you can also check out more blogs about34595-33-0

Reference：
Piperidine – Wikipedia,
Piperidine | C5H14706N – PubChem

Chemistry is traditionally divided into organic and inorganic chemistry. Computed Properties of C12H15N3. The former is the study of compounds containing at least one carbon-hydrogen bonds.In a patent£¬Which mentioned a new discovery about 34595-33-0

This invention relates to poly-substituted derivatives of the N-(benzyl)phenylacetamide type, pharmaceutical compositions comprising same, therapeutic uses thereof, more particularly in the fields of human and animal health. This invention also relates to a process for the preparation of such derivatives.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.Computed Properties of C12H15N3, you can also check out more blogs about34595-33-0

Reference£º
Piperidine – Wikipedia,
Piperidine | C5H14703N – PubChem

Chemistry is traditionally divided into organic and inorganic chemistry. Computed Properties of C12H15N3. The former is the study of compounds containing at least one carbon-hydrogen bonds.In a patent£¬Which mentioned a new discovery about 34595-33-0

This invention relates to poly-substituted derivatives of the N-(benzyl)phenylacetamide type, pharmaceutical compositions comprising same, therapeutic uses thereof, more particularly in the fields of human and animal health. This invention also relates to a process for the preparation of such derivatives.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.Computed Properties of C12H15N3, you can also check out more blogs about34595-33-0

Reference£º
Piperidine – Wikipedia,
Piperidine | C5H14703N – PubChem